Solution Biologics Sdn. Bhd

Solution Biologics Sdn. Bhd.("SOLBIO") has entered into a market authorisation, manufacturing and commercialisation agreement with CanSino Biologics Inc.based in Tianjin, China ("CanSinoBIO", SHSE:688185, HKEX:06185) for the supply of vaccines especially the Covid-19 vaccine into Malaysia. As part of the manufacturing agreement, SOLBIO is in the process of establishing a Fill & Finish Facility in our current building at Technology Park Malaysia. We are also responsible to market the vaccine, co-developed by CanSinoBIO and the Beijing Institute of Biotechnology, Academy of Military Medical Sciences (BIB). to the ASEAN countries namely Philippines, Thailand, Singapore, Myanmar, Vietnam, Cambodia, Laos and Brunei. Biologics and vaccines represent one of the fastest growing classes of therapeutic molecules in modern healthcare. The annual global biologics market is expected to be approximately USD 380 billion by 2024, representing a relatively higher growth rate (~8%) compared to conventional pharmaceuticals. Currently, more than 350 biologics are commercially presented in the biopharmaceuticals market. In the area of vaccines, there's no doubt that immunization saves millions of lives every year from vaccine-preventable diseases and one of the success stories in global health. More than 20 life-threatening diseases can now be prevented by immunization, and new vaccines for major killers like meningitis, cervical cancer, cholera and influenza are now being introduced in many countries. Today, vaccination is increasingly protecting health among people of all ages. With the incorporation of Solution Biologics Sdn. Bhd, as a biopharmaceutical company, SGB will enter into the life sciences business and will work to deliver vaccines and biologics that will help millions in Malaysia and the ASEAN region.